A&O advises Shionogi on its strategic joint venture with Apnimed for the development of therapies for obstructive sleep apnea and other sleep disorders
Related people
Matthew Appleton
Partner
London
David Ingles
Partner
New York
Tokutaka Ito
Partner
Tokyo
Jim Ford
Partner
London
Harsh Pais
Partner
London
Soumya Sharma
Senior Counsel
New York
John Hibbard
Senior Counsel
New York
Zara Sproul
Senior Associate
London
Megan McMellon
Associate
London
Lucy Chen
Associate
New York
Press contacts
For media enquiries relating to this topic, please contact:
Headlines in this article
Related news and insights
Publications: 26 March 2024
News: 21 March 2024
Allen & Overy advises arrangers on takeover of Encavis by KKR
News: 21 March 2024
News: 19 March 2024
A&O continues to be recognised for market-leading position in India
A&O advises Shionogi & Co., Ltd. (Shionogi), on its strategic collaboration and joint venture with Apnimed, Inc. (Apnimed) to develop therapies for obstructive sleep apnea (OSA) and other sleep disorders.
The transaction is structured as a 50:50 joint venture through a limited liability company incorporated in Delaware, United States, Shionogi-Apnimed Sleep Science, LLC.
The joint venture will leverage the Shionogi's innovation skills and small molecule drug discovery capabilities, and Apnimed's knowledge and R&D capabilities in the OSA field and approach to new combination treatments for OSA; with a view to realising promising solutions for OSA and other sleep disorders at a speed that cannot be achieved alone.
The A&O team was led by Matthew Appleton (Partner and Global Head of Healthcare Transactions, London), David Ingles (Partner, New York), Tokutaka Ito (Partner, Tokyo) and Jim Ford (Partner, and Global Head of Life Sciences, London), supported by Soumya Sharma (Senior Counsel, New York), Zara Sproul (Senior Associate, London), Megan McMellon (Associate, London) and Lucy Chen (Associate, New York).
The broader A&O team included Harsh Pais (Partner, London) and John Hibbard (Senior Counsel, New York).
For further information, please contact Clemency Wells on clemency.wells@allenovery.com.